
    
      This is a Phase II 24-week open-label study to evaluate the efficacy and safety of H.P.
      Acthar Gel Respository Injection, Corticotrophin( ACTH) administered to newly diagnosed
      patients with rheumatoid arthritis in conjunction with methotrexate, folllowed by a 24 week
      follow-up period. There will be a total of twenty (20) patients and two (2) treatment groups
      with 10 patients in each treatment group
    
  